title: Haemodynamic and clinical effects of ularitide in decompensated heart failure.
abstract: OBJECTIVE
  Ularitide is a synthetic form of urodilatin, a natriuretic peptide produced in the kidney with vasodilating, natriuretic, and diuretic effects, that offers promise for the management of decompensated heart failure (DHF). We assessed the efficacy and safety of ularitide in treating patients with DHF.
  
  
  RESULTS
  In this Phase II randomized, double-blind, placebo-controlled trial, 221 DHF patients received either placebo (n=53) or ularitide at 7.5 ng/kg/min (n=60), 15 ng/kg/min (n=53), or 30 ng/kg/min (n=55) as a 24-h continuous infusion. At 6 h, ularitide demonstrated a significant decrease in pulmonary capillary wedge pressure (P=0.052, P=0.000004, P=0.000002, respectively) and improved dyspnoea score in the 7.5, 15, and 30 ng/kg/min ularitide group (P=0.0026, P=0.0026, P=0.0013, respectively). Ularitide reduced systemic vascular resistance and increased cardiac index for the 15 and 30 ng/kg/min groups (P=0.017, P=0.00002, respectively). Systolic blood pressure (BP) decreased dose dependency. Heart rate and serum creatinine were unchanged through day 3. Most frequently reported drug-related adverse events through day 3 in all ularitide groups were dose-dependent BP decrease and hypotension.
  
  
  CONCLUSIONS
  Ularitide lowered cardiac filling pressures and improved dyspnoea without apparent early deleterious effects on renal function in DHF patients. These results suggest that ularitide may play a role in the management of DHF.
authors.affiliation: Kerckhoff-Klinik, Bad Nauheim, Germany.
authors.forename: Veselin
authors.initials: V
authors.lastname: Mitrovic
authors.forename: Petar M
authors.initials: PM
authors.lastname: Seferovic
authors.forename: Dejan
authors.initials: D
authors.lastname: Simeunovic
authors.forename: Arsen D
authors.initials: AD
authors.lastname: Ristic
authors.forename: Milutin
authors.initials: M
authors.lastname: Miric
authors.forename: Valentin S
authors.initials: VS
authors.lastname: Moiseyev
authors.forename: Zhanna
authors.initials: Z
authors.lastname: Kobalava
authors.forename: Klaus
authors.initials: K
authors.lastname: Nitsche
authors.forename: Wolf-Georg
authors.initials: WG
authors.lastname: Forssmann
authors.forename: Hartmut
authors.initials: H
authors.lastname: Lüss
authors.forename: Markus
authors.initials: M
authors.lastname: Meyer
mesh_terms: D009320:Atrial Natriuretic Factor / Q000008:administration & dosage* / Q000009:adverse effects; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D004232:Diuretics / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000008:administration & dosage / Q000009:adverse effects; D014554:Urination / Q000187:drug effects; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D004232:Diuretics; D010446:Peptide Fragments; D014665:Vasodilator Agents; C056452:Ularitide; D009320:Atrial Natriuretic Factor